Cure My Disease

Don't miss your cure!

 Log in / Sign up

New monthly shot could simplify anemia treatment for kidney patients

NCT ID NCT00560404

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a once-monthly injection of Mircera works as well as the standard epoetin alfa treatment for managing anemia in people on dialysis. About 233 adults with chronic kidney disease-related anemia participated. The goal was to see if Mircera could keep hemoglobin levels stable within a healthy range, offering a more convenient dosing schedule.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Mircera (methoxy polyethylene glycol-epoetin beta)
What this could lead to
If successful, this could offer dialysis patients a more convenient once-monthly injection option to manage anemia, reducing the need for more frequent dosing.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. The main risk is that Mircera may not control hemoglobin as effectively as standard treatment, potentially leading to anemia-related complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA

Contacts and locations

Locations

  • Study site

    Belo Horizonte, 30150-320, Brazil

  • Study site

    Brasília, 70390-108, Brazil

  • Study site

    Campinas, 13086-970, Brazil

  • Study site

    Campo Grande, 79002-073, Brazil

  • Study site

    Cariacica, 29152-230, Brazil

  • Study site

    Curitiba, 80050-350, Brazil

  • Study site

    Curitiba, 80440-020, Brazil

  • Study site

    Fortaleza, 60430160, Brazil

  • Study site

    Jaboatão dos Guararapes, 54400-170, Brazil

  • Study site

    Joinville, 89227-680, Brazil

  • Study site

    Juiz de Fora, 36036900, Brazil

  • Study site

    Londrina, 86015-000, Brazil

  • Study site

    Natal, 59020-110, Brazil

  • Study site

    Porto Alegre, 90035-903, Brazil

  • Study site

    Porto Alegre, 90610000, Brazil

  • Study site

    Ribeirão Preto, 14025-170, Brazil

  • Study site

    Rio de Janeiro, Brazil

  • Study site

    Salvador, 40110-060, Brazil

  • Study site

    São José do Rio Preto, 15090-000, Brazil

  • Study site

    São Luís, 65020-305, Brazil

  • Study site

    São Paulo, 01246-903, Brazil

  • Study site

    São Paulo, 01323-900, Brazil

  • Study site

    São Paulo, 01532-001, Brazil

  • Study site

    São Paulo, 03065-000, Brazil

  • Study site

    São Paulo, O4023, Brazil

  • Study site

    Sorocaba, 18030-210, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.